Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA
C Chen, J Lv, C Liu - Frontiers in Endocrinology, 2024 - frontiersin.org
Vericiguat, the newest soluble guanylate cyclase (sGC) drug, is potentially beneficial in
treating heart failure (HF). However, most studies have only confirmed the significant impact …
treating heart failure (HF). However, most studies have only confirmed the significant impact …
[HTML][HTML] Modified Zhenwu Decoction improved intestinal barrier function of experimental colitis through activation of sGC-mediated cGMP/PKG signaling
Y Xu, C Huang, H Xu, J Xu, KW Cheng, HL Mok… - Journal of …, 2024 - Elsevier
Background The invasion of luminal antigens and an aberrant immune response resulting
from a disrupted physical epithelial barrier are the key characteristics of ulcerative colitis …
from a disrupted physical epithelial barrier are the key characteristics of ulcerative colitis …
Abordări noi în tratamentul tulburărilor cognitive vasculare.
E Stratu, N Frîncu - Farmacist. ro, 2024 - search.ebscohost.com
Cerebrovascular cognitive disorders refer to a wide range of cognitive deficits caused by
cerebrovascular injuries. Current treatments are limited, focusing primarily on risk …
cerebrovascular injuries. Current treatments are limited, focusing primarily on risk …